Cholesterol in Medical Technology

New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management

TRILIPIX has now been studied in combination with the most commonly used doses of rosuvastatin calcium (5 mg, 10 mg, 20 mg) in patients with mixed dyslipidemia ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Data from a new study showed that Abbott 's TRILIPIX(R) (fenofibric acid) delayed-...

Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study

SYDNEY, Australia, Feb. 26 /PRNewswire/ -- Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularization) in patients with type 2 diabetes...

Aching Back? Cholesterol Medication Might Help

Study finds that using statins may be useful in treatment for degenerative disc disease LAS VEGAS, Feb. 22 /PRNewswire-USNewswire/ -- Back pain, a hallmark of degenerative disc disease, sends millions of people to their doctor. In fact, more than 80 percent of patients who undergo spine surg...

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

First Presentation of Pivotal Study Data in Pediatric Patients Presented at the American Heart Association's Annual Scientific Sessions 2008 PARSIPPANY, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. (DSI), announced today that results from the pivotal study supporting the use ...

Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels

Dr. John A. Rumberger and KGK Synergize Will Study Ingredient's Impact on North Americans NEW YORK, Sept. 25 /PRNewswire/ -- Daiichi Fine Chemical Co., Ltd. of Japan today announced that it has selected world-renowned Cardiologist Dr. John A. Rumberger and the Contract Research Division of...

VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis

Detailed lipid profile helps clinicians identify risk in patients, including non-diabetics, despite normal LDL levels and statin therapy BIRMINGHAM, Ala., July 21 /PRNewswire/ -- Using the VAP Cholesterol Test from Atherotech, researchers have identified a link between adiponectin and he...

Blueberry-Supplemented Diet Shows Promise in Lowering Cholesterol in Animal Trials

PORTLAND, Maine, June 19 /PRNewswire/ -- New research published in the British Journal of Nutrition (Br J Nutr., Dec. 17, PMID: 18081945, 2007) shows that blueberries may have a cardio-protective effect, by significantly lowering cholesterol. Lead scientist, Wilhelmina Kalt, Ph.D, from Agricul...

People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels

KGK Synergize Inc. presents Diabetinol(TM), test results SAN DIEGO, April 9, 2008 /PRNewswire/ -- Two new studies presented at the Experimental Biology Annual Meeting suggest that an all-natural dietary supplement made from citrus may help people with type 2 diabetes lower their blood ...

Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)

RALEIGH, N.C., Dec. 13 /PRNewswire/ -- The most recent study from the landmark Framingham trial demonstrates the clinical significance of knowing the number of LDL particles (LDL-P) by NMR in the management of a patient's risk for heart disease. This longitudinal outcomes study shows that low ...

Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary

- Patients on stable doses of statins treated for 3 months with 200 mg/week mipomersen experienced 48% further reduction in LDL-cholesterol - Integrated Phase 1 & 2 safety update continues to support mipomersen's favorable safety profile - Isis hosting Analyst & Investo...

Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes

MONTVALE, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI ) announced results of a series of preclinical studies designed to explain the mechanism underlying dysfunctional high density lipoprotein (HDL), that creates a defect in reverse cholesterol transport in p...

Fish Oil and Red Yeast Rice Studied for Lowering Blood Cholesterol

ROCHESTER, Minn., July 8 /PRNewswire-USNewswire/ -- A great deal of scientific evidence shows that cholesterol-reducing medications known as statins can help prevent coronary artery disease. Although the safety of these medications has been well documented, as many as 40 percent of patients wh...

New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol

The first prospective trial specifically designed to evaluate erectile function in ED patients with dyslipidemia CHICAGO, Dec. 10 /PRNewswire-FirstCall/ -- Results of the first prospective trial specifically designed to evaluate erectile function in erectile dysfunction (ED) pat...

Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol

Findings Appear Online on Aug. 5 in Nature Journal CLEVELAND, Aug. 7 /PRNewswire/ -- Researchers at Cleveland Clinic have identified the region within high density lipoprotein (HDL), the major carrier of "good" cholesterol, that can become dysfunctional within the artery wall, inhib...

CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume in Coronary Arteries

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- CSL Limited today announced results from a study published in the Journal of the American Medical Association that suggest infusions of a novel new drug, CSL-111, to acutely raise HDL ("good" cholesterol) levels, may reduce the amount of plaque in the co...

CSL Therapy That Mimics “Good” Cholesterol May Reduce Plaque Volume in Coronary Arteries

VICTORIA, Australia, March 27, 2007--CSL Limited today announced results from a study published in the Journal of the American Medical Association that suggest infusions of a novel new drug, CSL-111, to acutely raise HDL (“good” cholesterol) levels, may reduce the amount of plaque in t...

Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal

Kerri Penno Contributing Editor Medical conventions are challenged every day. Already in the new year, the effectiveness of cold medicine and the gold standard in breast cancer treatment have been challenged. Standards in cholesterol testing are the latest casualty of medical innovation....

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... in a broad Phase 3 program in patients who cannot adequately control their cholesterol levels with current therapies and who need new treatment options. ... also met each of its three secondary endpoints of reduction in apoB, total cholesterol and non-HDL-C. Genzyme continues to refine its European strategy fo...

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

...t it had a beneficial effect on lipids (molecules in the blood that include cholesterol and triglycerides). "It's extremely unusual to analyze the effect o...he combined effects of GH and sex-steroids on glucose tolerance, elevated cholesterol and insulin sensitivity--changes in older adults that occur as a result of ...

July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals

...nd risks. Some findings include: Vitamin B-3 (niacin): Niacin helps the body convert food to energy and helps improve circulation and cholesterol levels. Researchers have found that, in high doses, niacin can reduce low-density lipoprotein (LDL or "bad" cholesterol) and triglycerides and raise h...

New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed

...ide levels decreased from baseline in the nevirapine group 0.2 mg/dL and increased 28.1 mg/dL in the ATV/r group (p <0.0001). Mean increases in LDL cholesterol were 15 mg/dL in the nevirapine group and 10.5 mg/dL in the ATV/r group (p=0.011).(3) These results include patients who received once-daily nevirapin...

Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome

...e metabolite have demonstrated reductions in blood pressure, triglycerides, cholesterol levels, C-reactive protein, and fasting blood glucose levels. Enzyme levels...ed, pointing to an outstanding safety profile. Increases in HDL, the "good" cholesterol and increased insulin sensitivity have also been documented along with a ro...

New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%

...a Cambridge University Journal), clearly shows that Prebiotics reduce cholesterol and triglycerides, control body weight, and increase lifespan by 33%. ...biotics. Additionally, the "prebiotic" rats showed material reductions in cholesterol and body weight versus the control group. Significantly, the prebiot...

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients

... International Symposium on Atherosclerosis in Boston. "This study shows the effectiveness of pitavastatin to lower LDL [low-density lipoprotein] cholesterol in a group of elderly patients with primary hypercholesterolemia or combined dyslipidemia," said Professor Steen Stender, M.D., Ph.D., Gentofte Univer...

FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications

... The incidence and magnitude of changes in weight, prolactin, triglyceride, cholesterol and hepatic enzyme levels were greater in adolescents than adults. Sedation...high, elevations in triglyceride levels and modest mean elevations in total cholesterol have been observed with Zyprexa use. Potential consequences of weight...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

...-5.8+/-1.2 pounds], serum lipid profiles were significantly improved [total cholesterol -8.6+/-2.8 mg/dL; LDL cholesterol -4.5+/-2.2 mg/dL; triglycerides -15+/-3 percent], and there was a significa...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

...including: Blood Pressure: systolic blood pressure, diastolic blood pressure and heart rate Lipids: total cholesterol, LDL cholesterol and triglycerides Glycemic Parameters: fasting glucose, fasting insulin and insulin resistance Inflammatory Markers of Cardiovascula...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

...istory and tell your doctor if you: Have heart failure or other heart problems, or are on any medicines for high blood pressure, high cholesterol or heart failure, or for prevention of heart disease or stroke Take insulin or nitrate medicines Have a type of diabetic eye disease c...

Heart Disease Treatment Breakthrough

...terol and chances of suffering a heart attack or stroke could benefit from using Ateronon. The product can be taken alongside statins. Although cholesterol does put people at risk of suffering a heart attack or stroke, half of all heart attacks and three quarters of all strokes occur in people who do not ...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

... noted slightly more frequently in patients treated with pirfenidone (phosphate elevation, hyponatremia, lymphopenia, ALT elevation, AST elevation and cholesterol elevation). Of these laboratory abnormalities in pirfenidone patients, all but one case each of hyponatremia and lymphopenia were Grade 3. In four o...

Type 2 Diabetes: An Epidemic Among America's Youth

...ed training enables them to be experts in the care of endocrine diseases such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity. ...

Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient

...n the "diabetic state." By assessing factors like high blood pressure, bad cholesterol (LDL), blood sugar, triglycerides and weight, doctors can better predict th...ch as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity. ...

Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US

...diseases. Extensive Phase 1 testing and investigator-sponsored clinical studies have demonstrated the drug's potential to lower triglycerides, non-HDL cholesterol and LDL-cholesterol while raising HDL-cholesterol. In addition, placebo adjusted weight loss exceeding 5% in an 8-week placebo controlled study and 10...

Diabetes Experts Issue New Recommendations for Inpatient Glycemic Control - Call for Systemic Changes in Hospitals Nationwide

...zed training enables them to be experts in the care of endocrine disease such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity. For more information, please call the AACE office at 904-353-7878 or visit www.aace.com . About th...

Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity

... phase 3 obesity and diabetes Qnexa trials to date, coupled with the positive impact observed on other cardiometabolic factors such as blood pressure, cholesterol and glucose, is impressive and potentially represents a step forward in the treatment of obesity and obesity-related conditions," commented Leland Wil...

Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome

...endpoint of a reduction in Low Density Lipoprotein cholesterol (LDL-C). All patients in the FRANCIS trial receive... and statistically significant reductions in total cholesterol and non-HDL cholesterol - Varespladib's immediate and selective inhib...

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel

...in the EU each year.(5) Heart attack is a major manifestation of coronary heart disease, which occurs when the arteries become narrowed or clogged by cholesterol and fat deposits and cannot supply enough blood to the heart. In some cases, a blood clot may partially or totally block the blood supply to the heart...

Isis and Collaborators Present New Research at the ATVB Annual Conference

... of Cardiovascular Disease Prevention at the Harvard School of Public Health , presented a post-hoc analysis on a Phase 2 study in patients with high cholesterol who were treated with mipomersen as a single agent. Dr. Sacks' analysis showed that treatment with mipomersen reduced circulating apoC-III. ApoC-III ...

Pistachios Offer Protective Benefits Against Heart Disease, Type II Diabetes and Obesity

...s well as blood lipid markers associated with heart heath. The findings revealed that the full dose nut group had significantly reduced LDL and total cholesterol levels compared to the full dose muffin group, as well as a significant reduction in HbA1c from baseline in the full dose nuts compared to the other t...

New Weight Loss Hope for People with Diabetes

... 0.9 greater than those following a hospital-directed diet regimen. This weight loss was also associated with significant reductions in triglycerides, cholesterol and waist circumference. "New NutriSystem D is a lifeline for millions of people struggling to lose weight with diabetes," said Joe Redling, Cha...